VanEck Pharmaceutical ETF
PPH
129 hedge funds and large institutions have $685M invested in VanEck Pharmaceutical ETF in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 43 reducing their positions, and 24 closing their positions.
37.15% more ownership
Funds ownership: 78.35% → 115.5% (+37%)
29% more capital invested
Capital invested by funds: $531M → $685M (+$153M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 43
5% less funds holding
Funds holding: 136 → 129 (-7)
25% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 24
92% less call options, than puts
Call options by funds: $3.32M | Put options by funds: $41.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$139M |
| 2 |
Morgan Stanley
New York
|
+$38.7M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$34.9M |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$28.2M |
| 5 |
Jane Street
New York
|
+$23.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fisher Asset Management
Camas,
Washington
|
-$110M |
| 2 |
QC
Quadrature Capital
London,
United Kingdom
|
-$12.4M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$10.3M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$5.05M |
| 5 |
Two Sigma Investments
New York
|
-$4.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
S
151
SignatureFD
Atlanta,
Georgia
| – | -$5.92K | -65 | Closed |
|
|
SWA
152
SOA Wealth Advisors
New York
| – | -$3.16K | -35 | Closed |
|
153
Barclays
London,
United Kingdom
| – | -$1.82K | -20 | Closed |
|
|
GFPC
154
Global Financial Private Client
Sarasota,
Florida
| – | -$91 | -1 | Closed |
|
PPH Hedge Fund Activity: Q2 2025 in Review
129 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q2 2025, worth a combined $685M — up 29% from $531M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PPH and 18 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 41 added.
The largest buyer was Goldman Sachs, adding an estimated $139M. The largest seller was Fisher Asset Management, cutting an estimated $110M.
- 129 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q2 2025, down from 136 in Q1 2025.
- Funds reported $685M of VanEck Pharmaceutical ETF stock for Q2 2025, up 29% quarter-over-quarter.
- 18 funds opened new VanEck Pharmaceutical ETF positions in Q2 2025 and 24 closed out, a net change of -6 holders.
- The largest VanEck Pharmaceutical ETF buyer in Q2 2025 was Goldman Sachs, an estimated $139M added.
- The largest VanEck Pharmaceutical ETF seller in Q2 2025 was Fisher Asset Management, an estimated $110M sold.
Based on aggregated 13F filings for Q2 2025.